Enhancement of bone-bonding ability of bioactive titanium by prostaglandin E2 receptor selective agonist

Abstract Systemic administration of prostaglandin E2 receptor (EP4) selective agonist increases both bone formation and resorption, and consequently leads to an increase in bone mass. Although previous studies have reported that EP4 agonist enhanced bone remodeling and fracture healing, it was not k...

Full description

Saved in:
Bibliographic Details
Published in:Biomaterials 2008-03, Vol.29 (7), p.877-883
Main Authors: Onishi, Eijiro, Fujibayashi, Shunsuke, Takemoto, Mitsuru, Neo, Masashi, Maruyama, Takayuki, Kokubo, Tadashi, Nakamura, Takashi
Format: Article
Language:English
Subjects:
Advanced Basic Science
Animal experiment
Animals
Biomaterial
Bone and Bones - drug effects
Bone and Bones - surgery
Dentistry
Male
Microscopy, Electron, Scanning
Prostaglandin
Prostheses and Implants
Rabbits
Receptors, Prostaglandin E - agonists
Receptors, Prostaglandin E - metabolism
Receptors, Prostaglandin E, EP4 Subtype
Stress, Mechanical
Titanium
Titanium - pharmacology
Weight-Bearing
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Systemic administration of prostaglandin E2 receptor (EP4) selective agonist increases both bone formation and resorption, and consequently leads to an increase in bone mass. Although previous studies have reported that EP4 agonist enhanced bone remodeling and fracture healing, it was not known if EP4 agonist activates the bone–biomaterial interface. Bioactive titanium prepared by chemical and thermal treatment can bond to living bone and is suitable for use in clinical applications in cementless fixation devices. Therefore, we examined whether the administration of EP4 agonist enhances the bonding strength between bone and bioactive titanium. Bioactive titanium plates were inserted into the tibia bone of rabbits and examined histologically and biomechanically at 4, 8, and 16 weeks. EP4 agonist was administrated systemically every 2 weeks after surgery. A non-administrated control group, a low-dose group (10 μg/kg body weight (BW)), and a high-dose group (100 μg/kg BW) were compared. The bonding strength of bioactive titanium in the EP4 agonist groups was significantly higher than that in the control group at both 4 and 8 weeks, and enhanced bone remodeling and direct bonding around the bioactive titanium plates was observed only in the EP4 agonist groups at 4 weeks. EP4 agonist enhanced bone formation around the bioactive titanium plate, and achieved early direct bone bonding.
ISSN:0142-9612
1878-5905
DOI:10.1016/j.biomaterials.2007.10.028